Literature DB >> 8002094

Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients.

M G Bergeron1, M Bernier.   

Abstract

The profile of antibacterial activity of cefpirome was compared with that of nine other antimicrobial agents against 513 gram-negative bacteria isolated from septicemic patients. All strains were evaluated for their sensitivity by disc diffusion and broth dilution tests (MIC and MBC). Cefpirome was compared to cefazolin, cefuroxime, ceftazidime, ceftriaxone, aztreonam, imipenem, ticarcillin, tobramycin and ciprofloxacin. Among the five cephalosporins tested in this study, cefpirome was the most active against all isolates. The MIC50 and MIC90 of eight isolates of Acinetobacter calcoaceticus were 2 and 4 mg/l and those of 89 Pseudomonas aeruginosa were 2 and 8 mg/l, respectively. The MIC90 values of cefpirome for all other groups of bacteria were < or = 1 mg/l. The activity of cefpirome against gram-negative bacteria is at least as good as that of aztreonam and imipenem. The only drug showing a better profile of activity than cefpirome is ciprofloxacin. The scattergram of the 513 isolates for cefpirome MICs and inhibitory zones with the 30 micrograms disc, showed that only eight isolates were not susceptible to cefpirome. These data suggest that the in vitro activity of cefpirome is comparable to if not better than that of other beta-lactams and tobramycin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8002094     DOI: 10.1007/BF01739925

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Novel resistance selected by the new expanded-spectrum cephalosporins: a concern.

Authors:  C C Sanders
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

2.  The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus.

Authors:  G Seibert; D Isert; N Klesel; M Limbert; A Markus; E Schrinner
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

3.  The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres.

Authors:  D S Reeves; M J Bywater; H A Holt
Journal:  J Antimicrob Chemother       Date:  1993-03       Impact factor: 5.790

4.  Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers.

Authors:  R N Jones; M A Pfaller; S D Allen; E H Gerlach; P C Fuchs; K E Aldridge
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jul-Aug       Impact factor: 2.803

5.  Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329.

Authors:  M J Pucci; J Boice-Sowek; R E Kessler; T J Dougherty
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group.

Authors:  S Chamberland; J L'Ecuyer; C Lessard; M Bernier; P Provencher; M G Bergeron
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

7.  The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

8.  The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides.

Authors:  G Seibert; M Limbert; I Winkler; T Dick
Journal:  Infection       Date:  1983 Sep-Oct       Impact factor: 3.553

9.  Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.

Authors:  D Paradis; F Vallée; S Allard; C Bisson; N Daviau; C Drapeau; F Auger; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

10.  Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.

Authors:  R N Jones; C Thornsberry; A L Barry; L Ayers; S Brown; J Daniel; P C Fuchs; T L Gavan; E H Gerlach; J M Matsen
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

View more
  3 in total

1.  In vitro activity of cefpirome against selected clinical enterobacterial isolates with beta-lactamase-mediated resistance.

Authors:  L S Tzouvelekis; E Tzelepi; A F Mentis; N J Legakis
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

Review 2.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.

Authors:  J E Hoppe; E Rahimi-Galougahi; G Seibert
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.